loader
Please Wait
Applying Filters...

 Parand Darou Pharma  Parand Darou Pharma

X

List of Mavorixafor NDC API suppliers/manufacturers & exporters

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 Aptuit (Oxford) Ltd (1)

filter

01 MAVORIXAFOR (1)

filter

01 Germany (1)

URL Supplier Web Content
MAVORIXAFOR
POWDER (1kg/kg)
BULK INGREDIENT
71924-0064
2024-04-30
2025-12-31
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Looking for 690656-53-2 / Mavorixafor API manufacturers, exporters & distributors?

Mavorixafor manufacturers, exporters & distributors 1

53

PharmaCompass offers a list of Mavorixafor API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mavorixafor manufacturer or Mavorixafor supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mavorixafor manufacturer or Mavorixafor supplier.

PharmaCompass also assists you with knowing the Mavorixafor API Price utilized in the formulation of products. Mavorixafor API Price is not always fixed or binding as the Mavorixafor Price is obtained through a variety of data sources. The Mavorixafor Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Mavorixafor

Synonyms

558447-26-0, Amd-070, Amd070, Amd11070, Amd 070, Amd-11070

Cas Number

690656-53-2

Unique Ingredient Identifier (UNII)

0G9LGB5O2W

About Mavorixafor

Mavorixafor is an orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T-cells.

Mavorixafor Manufacturers

A Mavorixafor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mavorixafor, including repackagers and relabelers. The FDA regulates Mavorixafor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mavorixafor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Mavorixafor Suppliers

A Mavorixafor supplier is an individual or a company that provides Mavorixafor active pharmaceutical ingredient (API) or Mavorixafor finished formulations upon request. The Mavorixafor suppliers may include Mavorixafor API manufacturers, exporters, distributors and traders.

Mavorixafor NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mavorixafor as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Mavorixafor API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Mavorixafor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Mavorixafor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mavorixafor NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Mavorixafor suppliers with NDC on PharmaCompass.

Mavorixafor Manufacturers | Traders | Suppliers

Mavorixafor Manufacturers, Traders, Suppliers 1
37

We have 1 companies offering Mavorixafor

Get in contact with the supplier of your choice:

  1. Evotec
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Post Enquiry
POST ENQUIRY